Nabi Biopharmaceuticals (NASDAQ:NABI)

CAPS Rating: 4 out of 5

The Company leverage its experience and knowledge in powering the human immune system to develop and market products that target serious medical conditions in the areas of transplantation, infectious disease and hematology/oncology.

Recs

0
Player Avatar pbk100 (29.50) Submitted: 7/19/2011 12:12:16 PM : Underperform Start Price: $1.85 NABI Score: +12.45

"Data from this second [failed] trial may provide clues that could help explain the disappointing results from the first trial,"Lolz!There's nothing left. No coming back from this. their only product in trials doesn't work. At all.

Featured Broker Partners


Advertisement